

Product Datasheet

ST2/IL-33R Antibody - BSA Free

NBP2-53096

Unit Size: 100 ul

Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 3

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-53096

Updated 2/23/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-53096



NBP2-53096

ST2/IL-33R Antibody - BSA Free

Product Information

Unit Size	100 ul
Concentration	Concentrations vary lot to lot. See vial label for concentration. If unlisted please contact technical services.
Storage	Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.01% Thimerosal
Isotype	IgG
Purity	Antigen Affinity-purified
Buffer	0.1M Tris (pH 7), 0.1M Glycine, 10% Glycerol
Target Molecular Weight	63 kDa

Product Description


Host	Rabbit
Gene ID	9173
Gene Symbol	IL1RL1
Species	Mouse, Rat
Immunogen	Recombinant protein encompassing a sequence within the center region of human ST2/IL-33R. The exact sequence is proprietary.

Product Application Details


Applications	Western Blot, Immunohistochemistry
Recommended Dilutions	Western Blot 1:500 - 1:3000, Immunohistochemistry Validated for Immunohistochemistry from CiteAb

Images


Western Blot: IL1RL1 Antibody [NBP2-53096] - Rat tissue extract (50 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] diluted at 1:500.




Western Blot: IL1RL1 Antibody [NBP2-53096] - Whole cell extract (30 ug) was separated by 10% SDS-PAGE, and the membrane was blotted with ST2 antibody [N1C1] diluted at 1:500.




Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H₂O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with β -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 μ m. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 μ g/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 μ g/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with β -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35265208>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H₂O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with β -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 μ m. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 μ g/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 μ g/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with β -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35265208>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Western Blot: ST2/IL-33R Antibody [NBP2-53096] - p38 β mediates the IL-33-induced IA decrease. A, immunoblot analysis of p38 α & p38 β protein abundance in DRGs. Mouse brains were used as positive controls. Blots are representative of three independent experiments with β -tubulin serving as a loading control. B, time course of IA changes (left) & bar graph (right) indicating the effect of 50 ng/mL IL-33 on IA in the presence of JX-401 (50 nM, n = 8 cells). The application of 50 nM JX-401 (n = 6 cells) alone had no significant effect on IA. Arabic numerals indicate the points utilized for the example current traces. C, immunoblot analysis showing that the protein expression level of p38 β was significantly reduced in the p38 β -siRNA-treated groups, while the expression of p38 α was not affected. Blots are representative of three independent experiments with β -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. D, example traces (left) & bar graph (right) demonstrating the effects of 50 ng/mL IL-33 on IA in cells treated with control siRNA (NC-siRNA, n = 9 cells) or p38 β -siRNA (n = 11 cells). **p < 0.01 vs. control + NC-siRNA group, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35265208>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Western Blot: ST2/IL-33R Antibody [NBP2-53096] - ST2 mediates the IL-33 response on IA. A, Detection of ST2 transcripts in mouse DRGs. Neither the reverse-transcription negative control (without reverse transcriptase, -RT) nor nontemplate negative control (-H₂O) showed a signal. B, Immunoblot analysis of ST2 protein abundance in mouse DRGs. Blots are representative of three independent experiments with β -tubulin serving as a loading control. C, Colabeling (white arrows) of ST2 & NeuN, GS, CGRP, IB4 & NF200 in mouse DRG sections. Pre-incubation of ST2 antibody with excessive ST2 blocking peptide served as the specificity control of ST2 antibody. Scale bar, 50 μ m. D, Time course of IA changes (left) & bar graph (right) demonstrating that pretreating DRG neurons with an ST2 neutralizing antibody (ST2 Ab, 2 μ g/mL) prevented the IL-33-induced IA decrease (n = 9 cells). The application of 2 μ g/mL ST2 Ab alone did not affect IA (n = 7 cells). Arabic numerals indicate the points utilized for example current traces. **p < 0.01 vs. IL-33 without ST2 Ab, paired t test. E, Immunoblot analysis of ST2 protein abundance in the control siRNA (NC-siRNA) & ST2 siRNA-treated (ST2-siRNA) groups. Blots are representative of three independent experiments with β -tubulin serving as a loading control. **p < 0.01 vs. NC-siRNA, unpaired t test. F, Bar graph indicating that treatment with ST2-siRNA (n = 12 cells), but not NC-siRNA (n = 11 cells), abrogated the 50 ng/mL IL-33-induced IA decrease. *p < 0.05 vs. control + NC-siRNA, one-way ANOVA with a Bonferroni post hoc test. Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/35265208>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

B

Immunocytochemistry/ Immunofluorescence: ST2/IL-33R Antibody [NBP2-53096] - The IL-33-induced IA decrease requires Syk. A, effects of 50 ng/mL IL-33 on protein abundance of phospho-JAK2 (p-JAK2)/total JAK2 (t-JAK2). Blots are representative of three independent experiments w/ β -tubulin serving as a loading control. B, colabeling (white arrows) of ST2 & JAK2 & Syk in mouse DRG sections. Scale bar, 50 μ m. C, time course of IA changes (left) & bar graph (right) showing that pretreatment of DRG neurons w/ AG490 (10 μ M) did not affect IL-33-induced IA response (n = 8 cells). Application of 10 μ M AG490 alone did not affect IA (n = 7 cells). Arabic numerals indicate points utilized for example current traces. D, effects of 50 ng/mL IL-33 on p-Syk protein abundance in presence/absence of ST2 neutralizing antibody (ST2 Ab, 2 μ g/mL) in DRG cells. Blots are representative of three independent experiments w/ β -tubulin serving as a loading control. **p < 0.01 vs. control, unpaired t test. E-G, time course of IA changes showing that pretreating DRG neurons w/ R406/GS9973, but not KT-5720, prevented IL-33-induced IA response. Arabic numerals indicate points utilized for example current traces. H, bar graph showing effect of 50 ng/mL IL-33 on IA in cells pretreated w/ R406 (1 μ M, n = 11 cells), GS9973 (10 μ M, n = 8 cells), & KT-5720 (1 μ M, n = 9 cells). Application of 1 μ M R406 (n = 7 cells), 10 μ M GS9973 (n = 6 cells)/1 μ M KT-5720 (n = 7 cells) alone had no significant effect on IA. **p < 0.01 vs. control, paired t test. I, colabeling (white arrows) of ST2 & PKA in mouse DRG sections. Scale bar, 50 μ m. J, bar graph demonstrating effect of 20 μ M forskolin on IA in presence (n = 7 cells)/absence (n = 5 cells) of KT-5720 (1 μ M). ***p < 0.001 vs. forskolin w/out KT-5720, paired t test. Image collected & cropped by CiteAb from following publication (<https://pubmed.ncbi.nlm.nih.gov/35265208>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Zengliang He, Yan Song, Yongxiang Yi, Fengzhuo Qiu, Junhua Wang, Junwei Li, Qingwen Jin, Pradeep Kumar Sacitharan Blockade of IL-33 signalling attenuates osteoarthritis Clinical & Translational Immunology 2020-10-23 [PMID: 33133598]

Wang Y, Wang X, Qi R et al. Interleukin 33-mediated inhibition of A-type K⁺ channels induces sensory neuronal hyperexcitability and nociceptive behaviors in mice Theranostics 2022-02-14 [PMID: 35265208] (WB, Mouse)

Zhou J, Zhuang T, Ma P et al. MicroRNA-547-5p-mediated interleukin-33/suppressor of tumorigenicity 2 signaling underlies the genesis and maintenance of neuropathic pain and is targeted by the therapy with bone marrow stromal cells Mol Pain 2020-06-10 [PMID: 32513089] (WB, Rat)

Details:
Sprague-Dawley





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-53096

HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control
NBP2-24706PEP	ST2/IL-33R Antibody Blocking Peptide

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-53096

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

